Anecortave Acetate (Retaane)

Aetna considers anecortave acetate (Retaane) experimental and investigational with no covered indications and specifically does not cover it for age-related macular degeneration (ICD-10 H35.3110–H35.3293), glaucoma (H40.001–H42), or retinoblastoma (C69.20–C69.22). Coverage is denied because effectiveness has not been established, and the policy notes the listed indications are not all-inclusive so other uses may also be considered experimental/investigational and not covered unless otherwise specified.

"Aetna considers anecortave acetate (Retaane) experimental and investigational for the treatment of the following indications because its effectiveness has not been established (not an all-inclusive..."

Sign up to see full coverage criteria, indications, and limitations.